Helping Patients Fight ALL for Over 25 Years and Counting1

An acute lymphoblastic leukemia patient wearing a bandana over her hair flexes her bicep.

The original PEGylated asparaginase, designed to last longer

PEGylation links polyethylene glycol (PEG) polymer chains to a
molecule2 and provides several therapeutic benefits:

star icon

Reduces immunogenicity of the enzyme2,3

shield icon

Shields asparaginase from neutralizing antibodies2

calendar icon

Prolongs the half-life of ONCASPAR, allowing for administration every 2 weeks; mean half-life is approximately 5.8 days following a single intramuscular injection and 5.3 days following a single intravenous infusion1,3

Storage and handling1

ONCASPAR® (pegaspargase) carton

Store in the original carton to protect from light

thermometer

Store ONCASPAR refrigerated at 2°C to 8°C (36°F to 46°F). Unopened vials may be stored at room temperature (15°C to 25°C [59°F to 77°F]) for no more than 48 hours

Diluted ONSCASPAR solution in IV Bag

When ONCASPAR is diluted for IV administration, the diluted solution should be used immediately. If immediate use is not possible, the diluted solution should be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 48 hours. Protect infusion bags from direct sunlight

Caution! Do not administer
ONCASPAR if the drug has been1

no more than 48 hours icon

Stored as unopened vials at room temperature for more than 48 hours

no shake icon

Shaken or vigorously agitated

not freeze icon

Frozen

Contact a representative

If you have questions or would like to learn more about ONCASPAR, let us know and a representative will get in touch

CONTACT US
A doctor speaks with a Servier representative.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION Section

CONTRAINDICATIONS

  • History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR (pegaspargase) or to any of the excipients.
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.
  • Severe hepatic impairment.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR (pegaspargase) or to any of the excipients.
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.
  • Severe hepatic impairment.

WARNINGS and PRECAUTIONS 

Anaphylaxis and Serious Hypersensitivity Reactions: Anaphylaxis and serious hypersensitivity reactions can occur. The risk of serious hypersensitivity reactions is higher in patients with known hypersensitivity to (E.) coli derived L-asparaginase formulations. Premedicate patients 30-60 minutes prior to administration of ONCASPAR. Observe patients for 1 hour after administration in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Discontinue ONCASPAR in patients with serious hypersensitivity reactions.

Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis, can occur. Discontinue ONCASPAR in patients with serious thrombotic events.

Pancreatitis: Pancreatitis can occur. Fatal outcomes have been reported. Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Discontinue ONCASPAR in patients where pancreatitis is suspected. If pancreatitis is confirmed, do not resume ONCASPAR. 

Glucose Intolerance: Glucose intolerance can occur and, in some cases, be irreversible. Monitor serum glucose. 

Hemorrhage: Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia can occur. Evaluate patients with signs and symptoms of hemorrhage with coagulation parameters including PT, PTT, and fibrinogen. Consider appropriate replacement therapy in patients with severe or symptomatic coagulopathy. Discontinue ONCASPAR for severe or life-threatening hemorrhage. 

Hepatotoxicity: Hepatotoxicity and abnormal liver function can occur. Evaluate bilirubin and transaminases at least weekly during cycles of treatment through at least 6 weeks after the last dose. In the event of serious liver toxicity, discontinue ONCASPAR and provide supportive care.

ADVERSE REACTIONS

The most common grade 3 and 4 adverse reactions with ONCASPAR (>5%) included hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections. 

INDICATIONS AND USAGE

ONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with:

  • First-line acute lymphoblastic leukemia (ALL)
  • ALL and hypersensitivity to native forms of L-asparaginase
Please see Full Prescribing Information.